Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-168.57M |
| Operating Margin | 0.00% |
| Return on Equity | -147.40% |
| Return on Assets | -27.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.60 |
| Price-to-Book | 7.17 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.08 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $278.29M |
| Float | $169.91M |
| % Insiders | 6.51% |
| % Institutions | 82.78% |
Volatility is currently contracting